文献速递乳腺癌

HER2阳性早期乳腺癌化疗精简:是否仍需卡铂?

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
PubMed 文献 · Eur J Cancer · 2026-09-03

本综述评估在HER2阳性早期乳腺癌(HER2+ eBC)的(新)辅助方案中加入卡铂的依据,并批判性审视其在未选择患者群体中的常规使用。早期转化和临床研究曾提示卡铂联合紫杉类化疗与抗HER2治疗可能获益,但近期随机试验未能证明增量优势且提示毒性增加。以HER2DX基因组检测为代表的预后和预测生物标志物有望识别可能从卡铂获益的高危亚组,结论是不应在未选择的HER2+ eBC中常规加用卡铂,而推荐生物标志物驱动的个体化策略。

要点

  • 近期随机试验未证明卡铂在未选择HER2+ eBC中带来增量获益,且毒性增加。
  • 卡铂不应在未选择的HER2+早期乳腺癌中常规加入(新)辅助方案。
  • HER2DX等生物标志物有望筛选可能从卡铂获益的高危患者亚组。

核心结论

  • 卡铂不应在未选择的HER2阳性早期乳腺癌中常规加入(新)辅助方案,推荐生物标志物驱动的个体化策略以优化患者选择和治疗算法。

研究设计与样本

  • 本综述评估在HER2阳性早期乳腺癌(新)辅助方案中加入卡铂的依据,并批判性审视其在未选择患者群体中的常规使用。

主要发现

  • 早期转化和临床研究曾提示在紫杉类化疗联合抗HER2治疗基础上加用卡铂可能获益。
  • 近期随机试验未能证明卡铂带来增量优势,并引发对毒性增加的担忧。
  • HER2DX基因组检测等新兴预后和预测生物标志物有望识别可能从卡铂获得有意义获益的高危患者亚组。

临床怎么用

  • 不应在未选择的HER2阳性早期乳腺癌(新)辅助治疗中常规加用卡铂。
  • 可考虑采用生物标志物驱动的个体化策略筛选卡铂获益人群,以优化治疗算法和成本效益比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past two decades, targeted anti-HER2 therapies have transformed management of HER2-positive early breast cancer (HER2 + eBC), enabling chemotherapy de-escalation without compromising efficacy. This review assesses the rationale for incorporating carboplatin into (neo)adjuvant regimens and critically examines its routine use in unselected patient populations with HER2-positive eBC. While initial translational and early clinical studies suggested that adding carboplatin to taxane-based chemotherapy combined with anti-HER2 therapy might be beneficial, more recent randomized trials have failed to demonstrate incremental advantage and have raised concerns about increased toxicity. Emerging prognostic and predictive biomarkers, most notably the HER2DX genomic assay, hold promise for identifying high-risk patient subgroups who may derive meaningful benefit from carboplatin. We conclude that carboplatin should not be routinely added in unselected HER2-positive early breast cancer, but rather, a biomarker-driven, personalized strategy is recommended to enhance patient selection, refine the treatment algorithm, and maximize the cost-to-benefit ratio.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Conforti F, Canzian J, Tinterri B, et al. Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin? Eur J Cancer. 2026. PMID: 42700699. doi:10.1016/j.ejca.2026.117015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。